PharmaEngine, Inc.

PharmaEngine, Inc. is a biopharmaceutical company focused on the research, development, and commercialization of novel therapeutics in oncology. Founded in 2002 and headquartered in Taipei, the company operates under a virtual pharmaceutical company business model, leveraging international collaborations to advance drug development efficiently. Its primary marketed product, ONIVYDE, is an innovative liposomal formulation of irinotecan designed for the treatment of patients with metastatic pancreatic cancer, and it has received regulatory approvals in multiple regions. In addition to its commercial product, PharmaEngine maintains an active pipeline, including investigational candidates such as PEP07, a CHK1 inhibitor currently in Phase 1 clinical trials for hematological and solid tumors, and PEP08, a PRMT5 inhibitor in early stages of development. By concentrating on cutting-edge therapies for a range of cancers—including pancreatic, gastric, brain, breast, liver, and prostate—PharmaEngine plays a significant role in Taiwan's biotechnology and healthcare sectors. The company is recognized for its strategic licensing and partnerships, contributing both to the domestic pharmaceutical landscape and the global oncology market.